Item 8.01. Other Events.
On June 16, 2020, Progenics Pharmaceuticals, Inc. (the "Company") issued a press
release announcing that, at a special meeting of its stockholders held on
June 16, 2020 (the "Special Meeting"), the Company's stockholders voted to
approve the adoption of the Amended and Restated Agreement and Plan of Merger,
dated as of February 20, 2020, by and among the Company, Lantheus Holdings,
Inc., a Delaware Corporation ("Lantheus Holdings") and Plato Merger Sub, Inc., a
Delaware corporation and wholly-owned subsidiary of Lantheus Holdings ("Merger
Sub"), pursuant to which Merger Sub will be merged with and into the Company
(the "Merger"), with the Company surviving the Merger as a wholly-owned
subsidiary of Lantheus Holdings. At the Special Meeting, the Company's
stockholders also voted to approve, on an advisory (non-binding) basis, the
compensation that will or may be paid or provided by the Company to its named
executive officers in connection with the Merger. A copy of the press release is
attached as Exhibit 99.1 hereto and incorporated herein by reference.
The Company expects to file a Form 8-Kunder Item 5.07 with the Securities and
Exchange Commission reporting the voting results within the required time period
for such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
99.1 Press Release, dated June 16, 2020--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
PROGENICS PHARMACEUTICALS, INC. 
